Results 91 to 100 of about 88,356 (287)

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Targeted drug conjugates in cancer therapy: Challenges and opportunities

Pharmaceutical Science Advances
Traditional chemotherapy is often accompanied by off-target toxicity, resulting in adverse side effects and driving the development of targeted therapies.
Geng Jia, Yuqi Jiang, Xiaoyang Li
doaj   +1 more source

Supplementary Table S1 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

, 2008
Supplementary Table S1 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic ...
Eileen Turcott (15041066), Ivan Stone (15036102), Hans-Peter Gerber (4261570), Lori Westendorf (15036087), Charlotte F. McDonagh (14973178), Stephen C. Alley (1897735), Django Sussman (1934839), Martha Anderson (1934836), Paul J. Carter (3387371), Tiffany Feist (15036093), Jamie Miyamoto (15041069), Kristine M. Kim (15036084), Lindsay L. Brown (15036090), Robert Lyon (15036096)   +13 more
core   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Targeted Fluorogenic Cyanine Carbamates Enable In Vivo Analysis of Antibody-Drug Conjugate Linker Chemistry

, 2021
Antibody-drug conjugates (ADCs) are a rapidly emerging therapeutic platform. The chemical linker between the antibody and the drug payload plays an essential role in the efficacy and tolerability of these agents.
Sierra , Marker, Martin, Schnermann, Donald, Caldwell, Nimit, Patel, Brad, St Croix, Syed, Usama, Yang, Feng, Joseph, Kalen   +7 more
core   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates

, 2017
Muhammad Kalim,1 Jie Chen,1 Shenghao Wang,1 Caiyao Lin,1 Saif Ullah,1 Keying Liang,1 Qian Ding,1 Shuqing Chen,2 Jinbiao Zhan1 1Department of Biochemistry and Genetics, School of Medicine, 2Department of Pharmaceutical Analysis, College of Pharmaceutical
Ullah S, Lin C, Chen J, Wang S, Liang K, Kalim M, Ding Q, Chen S, Zhan JB   +8 more
core  

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Antibody-Drug Conjugate Sequencing in Metastatic Breast Cancer

healthbook TIMES. Oncology Hematology
Antibody-drug conjugates (ADCs) have redefined the therapeutic paradigm of metastatic breast cancer by combining targeted antibody specificity with potent cytotoxic payloads. The regulatory approvals of sacituzumab govitecan (SG), trastuzumab deruxtecan (
Benjamin Müller, Marcus Vetter
doaj   +1 more source

Supplemental Figure Legend from Anti-Endosialin Antibody–Drug Conjugate: Potential in Sarcoma and Other Malignancies

, 2015
Supplemental Figure Legend from Anti-Endosialin Antibody–Drug Conjugate: Potential in Sarcoma and Other ...
Cecile Rouleau (14974161), Bruce C. Horten (15072706), Robert Smale (14974167), Stephanie D. Roth (15072697), Steven M. Schmid (15072709), Roy Krumbholz (328645), Kenneth J. Munroe (15072700), Jay Harper (203272), Tessa L. Green (15072703), Beverly A. Teicher (9030386), Diego A. Gianolio (1831690)   +10 more
core   +1 more source